Reviewed November 16, 2026

OpenEvidence

Private
openevidence.com

Clinical information and AI workflows

Company overview

Revenue
~$300M run rate
July 2026 · Estimate
Reference valuation
$15B
Funding round · reported · Sep 2026
Primary customer
Clinicians[1]
Commercial model
Free clinician access[1]

Both the financing reference and revenue estimate are sourced to Sacra. Advertising-supported clinical software has different economics from insurance or care delivery.[1]

Monthly consultations
~20M[1]
January 2026 · reported

Revenue history

Revenue

Annualized revenue · USD

+3,697%

Jul 2026 vs. Dec 2024 · calculated change; not annualized

$0$200M$400MDec 2024Dec 2025Jul 2026
Revenue observations and evidence
PeriodUSDEvidence
$8MEstimate
$150MEstimate
$300MEstimate

Sacra · company research and financial history ↗

Annualized revenue observations are point-in-time measures, not completed annual revenue.

Points show dated observations at equal spacing; intervening performance is not measured.

Products, customers & revenue model

ProductCustomerCommercial model
Clinical search[1]Clinicians

Free clinician access

Advertising[1]Pharma and medical-device companies

Advertising inventory

Business economics

What drives the business
Clinician adoption drives advertiser reach. Clinical consultations are usage, not patient outcomes or revenue.[1]

Leadership & functional coverage

Selected leaders supported by the linked sources; dated appointments retain their source context. This is not a complete org chart. Advisory roles are labeled.

LeaderRoleFunction / context
Daniel NadlerCofounder & CEOCompany leadership · July 2026 interview[2]
Zachary ZieglerCofounder & CTOTechnology · May 2026 conference appearance[3]

Dated financial disclosures

DateEvent
July 2026~$300M run rate[1]

Estimate. Revenue observation; separate from the financing date.

Sep 2026$15B reference valuation[1]

Funding round · reported

Sector comparison

Same vertical; different business models and reporting periods. Values are not directly comparable revenue multiples.

CompanyRevenue measureReference valuation
OpenEvidence~$300M run rate

July 2026

$15B

Sep 2026

Devoted Health~$3.27B revenue

FY2024

$25B

Oct 2026

Ro~$3.02B run rate

October 2026

$7B

Feb 2022

Commure~$105M ARR

March 2024

$7B

May 2026

Abridge~$100M ARR

May 2025

$5.3B

Jun 2025

Open research questions

  • ↗How does monetization scale while maintaining clinician trust?

Sources & definitions

Financial history preserves the source’s measurement basis. ARR, annualized revenue, completed-year sales and transaction volume are distinct. Product economics are Plank analysis of the cited business model; open questions are not asserted findings.

  1. 1Sacra · company research and financial history
  2. 2Goldman Sachs · founder interview
  3. 3STAT · Breakthrough Summit interview